Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01019434
Other study ID # EORTC-26082-22081
Secondary ID EORTC-26082EORTC
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2009
Est. completion date March 2014

Study information

Verified date July 2018
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with temsirolimus or temozolomide in treating patients with glioblastoma.

PURPOSE: This randomized phase II trial is studying giving radiation therapy together with temsirolimus to see how well it works compared with giving radiation therapy together with temozolomide in treating patients with newly diagnosed glioblastoma.


Description:

OBJECTIVES:

Primary

- Document the activity profile of temsirolimus by the evaluation of overall survival at 1 year in patients with newly diagnosed glioblastoma multiforme, without methylation of the MGMT gene promoter, treated with temsirolimus before and concomitantly with radiotherapy, followed by temsirolimus maintenance therapy.

Secondary

- Investigate safety and tolerability of this therapy regimen in these patients.

- Assess progression-free survival and overall survival of these patients.

- Assess biomarkers in the tumor tissue relevant to temsirolimus and disease state, and their correlation to clinical outcome in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to institution, age in years (< 50 vs ≥ 50), Karnofsky performance status (PS) (< 80% vs ≥ 80%) OR ECOG PS (0 or 1 vs 2), and corticosteroid use (yes vs no). Patients are randomized to 1 of 2 treatment arms.

- Arm I: Within 7 weeks after surgery or open biopsy, patients undergo radiotherapy 5 days a week for 6 weeks and receive oral temozolomide concurrently once daily for 6 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant oral temozolomide once daily on days 1-5. Treatment with adjuvant temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression and unacceptable toxicity.

- Arm II: Within 7 weeks after surgery or open biopsy, patients undergo radiotherapy 5 days a week for 6 weeks. Patients also receive temsirolimus IV over 30-60 minutes once weekly beginning 7 days before initiation of radiotherapy. After completion of chemoradiotherapy, patients receive maintenance temsirolimus IV once weekly in the absence of disease progression and unacceptable toxicity.

Frozen tumor biopsies or paraffin-embedded tumor material obtained from surgery or open biopsy and blood samples are collected for analysis of molecular markers, determination of the methylation status of the MGMT gene promoter (before randomization and at a later time), and other studies.

After completion of study therapy, patients are followed every 3 months.


Recruitment information / eligibility

Status Completed
Enrollment 111
Est. completion date March 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed (by open brain biopsy or from a neurosurgical resection of the tumor) supratentorial glioblastoma multiforme (GBM)

- WHO grade IV disease

- Newly diagnosed disease

- Must provide demonstration of an unmethylated MGMT-promoter

- At least 2 weeks and no more than 6 weeks since surgery or open biopsy

- Tumor tissue specimens (paraffin-embedded and/or frozen) from the GBM surgery or open biopsy must be available for central pathology review, MGMT status determination, and exploratory analysis of PI3-K/Akt/mTOR targets (P70S6K)

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy = 12 weeks

- WBC = 3.0 x 10^9/L

- Absolute neutrophil count = 1.5 x10^9/L

- Platelet count = 75.0 x 10^9/L

- Hemoglobin = 10.0 g/dL

- Bilirubin = 1.5 times the upper limit of normal (ULN)

- Alkaline phosphatase = 2.5 x ULN

- AST and/or ALT = 2.5 x ULN

- Serum creatinine < 1.5 x ULN

- PT and PTT normal

- Negative pregnancy test

- Not pregnant or nursing

- Fertile patients must use highly effective contraception

- No ischemic heart disease in the past 6 months

- 12-lead ECG normal

- No history of stroke

- No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

- No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer (with no subsequent evidence of recurrence)

- No serious concurrent systemic disorder including any of the following that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol:

- Active infection

- HIV infection

- Cardiac disease

- QTc prolongation > 450/470 msec (males/females)

- No patients with a congenital long-QT-syndrome in their own or family medical history, unless eligible at the investigator's discretion

- No known hypersensitivity to the study treatment

- No known hypersensitivity to antihistamines or other medical reason that prohibits the intake of antihistamines

- No current alcohol dependence or drug abuse

- No legal incapacity or limited legal capacity

- Able to undergo a gadolinium-enhanced MRI of the brain

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- At least 4 weeks since prior and no concurrent investigational agent

- No prior stereotactic biopsy

- At least 30 days since prior drug therapy that has not received regulatory approval for any indication

- No chemotherapy within the past 5 years

- No prior chemotherapy for a brain tumor

- No prior radiotherapy to the head

- No other concurrent anticancer therapy

- No concurrent anticoagulation therapy except low-dose prophylactic low molecular weight heparin

- Concurrent steroid therapy allowed provided patient is on a stable or decreasing dose for = 1 week

- At least 14 days since prior and no concurrent enzyme-inducing anticonvulsants (e.g., carbamazepine, phenobarbital, and phenytoin)

- No concurrent strong inducers or inhibitors of CYP3A4

- No concurrent planned surgery for other diseases (e.g., dental extraction)

- No placement of Gliadel® wafer during prior surgery

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
temozolomide
TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
temsirolimus
CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.

Locations

Country Name City State
Belgium UZ Leuven Leuven
France Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau Nantes-Saint Herblain
France CHU Pitie-Salpetriere AP-HP Paris
Germany Universitaetsklinikum Freiburg Freiburg
Germany Universitatsklinikum Heidelberg Heidelberg
Italy Ospedale Bellaria Bologna
Netherlands Medisch Centrum Haaglanden - Westeinde Den Haag
Netherlands Erasmus MC - Daniel den Hoed Cancer Center Rotterdam
Spain ICO Badalona - Hospital Germans Trias i Pujol Badalona
Switzerland Ospedale Regionale Bellinzona e Valli Bellinzona
Switzerland UniversitaetsSpital Zuerich Zurich
United Kingdom Clatterbridge Cancer Centre NHS Foundation Trust Bebington Wirral
United Kingdom Western General Hospital Edinburgh

Sponsors (2)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC Pfizer

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Italy,  Netherlands,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival at 1 year 1 year
Secondary Percentages of worst Adverse Events or Laboratory Event grades as measured by CTCAEs Version 4.0 criteria end of trial
Secondary Progression-free survival (PFS) probability at 6 months and at 12 months, and overall survival (OS) probability at 2 years end of trial
Secondary Correlation between biomarkers relevant to temsirolimus and PFS and OS end of trial
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma Phase 2
Recruiting NCT00887146 - Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00621686 - Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Terminated NCT00227032 - Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme Phase 1
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Terminated NCT00243022 - Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00278278 - Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Phase 3
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Completed NCT00416819 - Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma N/A
Completed NCT00052286 - Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer N/A
Completed NCT00006093 - EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT00004129 - Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Phase 1
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003417 - Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00008008 - Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Phase 2
Completed NCT00003464 - Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme Phase 2
Completed NCT00003020 - LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases Phase 1
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2